University of Texas's MD Anderson Cancer: Neoadjuvant Combination Immunotherapy Improves Outcomes for Early Stage Non-Small Cell Lung Cancer
February 19, 2021
February 19, 2021
HOUSTON, Texas, Feb. 19 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Feb. 18, 2021:
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration . . .
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration . . .